CN111770936A - 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症 - Google Patents

抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症 Download PDF

Info

Publication number
CN111770936A
CN111770936A CN201980007986.6A CN201980007986A CN111770936A CN 111770936 A CN111770936 A CN 111770936A CN 201980007986 A CN201980007986 A CN 201980007986A CN 111770936 A CN111770936 A CN 111770936A
Authority
CN
China
Prior art keywords
antibody
variable region
chain variable
seq
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980007986.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·卡尔顿
D·费尔特奎
O·德·黑瑙
T·P·雷利
T·陈
Y·冯
S·P·B·黄
M·周
R·苏雷什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN111770936A publication Critical patent/CN111770936A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980007986.6A 2018-01-12 2019-01-11 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症 Pending CN111770936A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862616716P 2018-01-12 2018-01-12
US62/616,716 2018-01-12
US201862650047P 2018-03-29 2018-03-29
US62/650,047 2018-03-29
US201862679412P 2018-06-01 2018-06-01
US62/679,412 2018-06-01
PCT/US2019/013134 WO2019140150A1 (en) 2018-01-12 2019-01-11 Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Publications (1)

Publication Number Publication Date
CN111770936A true CN111770936A (zh) 2020-10-13

Family

ID=65279657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980007986.6A Pending CN111770936A (zh) 2018-01-12 2019-01-11 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症

Country Status (12)

Country Link
US (2) US11572405B2 (https=)
EP (1) EP3737696A1 (https=)
JP (2) JP2021510697A (https=)
KR (1) KR20200108868A (https=)
CN (1) CN111770936A (https=)
AU (1) AU2019207812A1 (https=)
BR (1) BR112020013144A2 (https=)
CA (1) CA3084370A1 (https=)
IL (1) IL275940A (https=)
MX (1) MX2020006171A (https=)
SG (1) SG11202005323SA (https=)
WO (1) WO2019140150A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022122026A1 (en) * 2020-12-11 2022-06-16 Genesail (Shanghai) Co., Ltd. A modified oncolytic virus, composition and use thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
EP3288982A1 (en) 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
WO2017132508A1 (en) * 2016-01-27 2017-08-03 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2019140150A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
EP4127724A1 (en) * 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
EP4216943A1 (en) * 2020-09-24 2023-08-02 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2023192478A1 (en) * 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
US20240400668A1 (en) * 2022-07-29 2024-12-05 Jinfeng Laboratory Non-human mammalian model expressing il-8 and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058797A2 (en) * 2002-12-16 2004-07-15 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (il-8)
CN101213297A (zh) * 2005-05-09 2008-07-02 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
US20160347849A1 (en) * 2015-05-29 2016-12-01 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2017152085A1 (en) * 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
US20170274073A1 (en) * 2014-09-15 2017-09-28 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5652338A (en) 1988-03-16 1997-07-29 The United States Of America As Represented By The Department Of Health And Human Services Neutrophil chemotactic factor
JPH03505037A (ja) 1988-05-02 1991-11-07 大日本製薬株式会社 ヒト好中球走化因子ポリペプチドの製造方法
KR100197110B1 (ko) 1988-08-29 1999-06-15 로버트 란만 활성 사람 호중구 화학주성 인자 폴리펩티드의 제조방법
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5427098A (en) 1988-12-22 1995-06-27 Biofield Corp. Noninvasive method for determining treatment based upon lesion cell proliferation measurements
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5776457A (en) 1991-03-29 1998-07-07 Genentech, Inc. Antibodies to human PF4A receptor and compositions thereof
US5840856A (en) 1991-03-29 1998-11-24 Genentech, Inc. Antibodies to a human PF4 superfamily receptor
US5919896A (en) 1991-03-29 1999-07-06 Genentech, Inc. PF4A receptor
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
CA2105998C (en) 1991-03-29 2003-05-13 James Lee Human pf4a receptors and their use
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
US6087475A (en) 1991-12-19 2000-07-11 Genentech, Inc. PF4A receptor
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
US6200558B1 (en) 1993-09-14 2001-03-13 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6448379B1 (en) 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
US5702946A (en) 1994-03-03 1997-12-30 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
US5874080A (en) 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma
GB2303238B (en) 1994-04-28 1998-02-18 Music Vending Inc Vending system
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US5707621A (en) 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
AU4771696A (en) 1995-01-23 1996-08-14 Regents Of The University Of California, The Methods for the treatment of acid aspiration-induced acute lung injury
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997039772A1 (fr) 1996-04-19 1997-10-30 Chugai Seiyaku Kabushiki Kaisha Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif
EP1854481B1 (en) 1996-04-23 2014-07-16 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient
CA2254782A1 (en) 1996-06-26 1997-12-31 Kenji Yokoi Remedies for acute pulmonary injuries due to indirect causes containing anti-il-8 antibody as the active ingredient
CA2268085A1 (en) 1996-10-22 1998-04-30 Go Wakabayashi Sepsis remedy comprising anti-il-8 antibody as active ingredient
EP1415998A3 (en) 1997-02-21 2005-11-23 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
CN1068524C (zh) 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
AU2559799A (en) 1998-01-22 1999-08-09 Genentech Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6419944B2 (en) 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6419934B1 (en) 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
IL129180A0 (en) 1999-03-25 2000-02-17 Technion Res & Dev Foundation Method and pharmaceutical composition for wound healing
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EP1210424B1 (en) 1999-08-23 2007-02-07 Dana-Farber Cancer Institute, Inc. Novel b7-4 molecules and uses therefor
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
DE19952622A1 (de) 1999-11-02 2001-05-10 Bayer Ag Verfahren zur Herstellung von rekombinantem Interleukin-8 und Interleukin-8 Muteinen
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US6420346B1 (en) 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
AR030753A1 (es) 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
US7427665B2 (en) 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002077172A2 (en) 2001-03-23 2002-10-03 Board Of Regents, The University Of Texas System Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
JP2005520854A (ja) 2002-03-19 2005-07-14 アブジェニックス・インコーポレーテッド 慢性閉塞性肺疾患（ｃｏｐｄ）を治療するための方法
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20050142136A1 (en) 2003-10-23 2005-06-30 Lary Suva Anti-interleukin 8 therapy for tumor osteolysis
CA2588613C (en) 2004-11-23 2010-09-14 Pip Co., Ltd. Built-in wall water service box
MX2007013058A (es) 2005-04-20 2008-02-22 Amgen Fremont Inc Anticuerpos monoclonales de alta afinidad completamente humanos para interleucina-8 y epitopes para dichos anticuerpos.
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US20110105724A1 (en) 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
JP6211597B2 (ja) 2012-05-01 2017-10-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規抗体
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
JO3580B1 (ar) 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
US11299543B2 (en) 2016-06-02 2022-04-12 Bristol-Myers Squibb Company Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment
LT3463457T (lt) 2016-06-02 2023-09-11 Bristol-Myers Squibb Company Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą
WO2017210637A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
WO2019140150A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058797A2 (en) * 2002-12-16 2004-07-15 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (il-8)
CN101213297A (zh) * 2005-05-09 2008-07-02 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
US20170274073A1 (en) * 2014-09-15 2017-09-28 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
US20160347849A1 (en) * 2015-05-29 2016-12-01 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2017152085A1 (en) * 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIE BAI ET AL: "Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade", ONCOTARGET, vol. 8, no. 66, 25 November 2017 (2017-11-25), pages 110695 - 110698 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022122026A1 (en) * 2020-12-11 2022-06-16 Genesail (Shanghai) Co., Ltd. A modified oncolytic virus, composition and use thereof

Also Published As

Publication number Publication date
EP3737696A1 (en) 2020-11-18
CA3084370A1 (en) 2019-07-18
AU2019207812A1 (en) 2020-07-23
US11572405B2 (en) 2023-02-07
IL275940A (en) 2020-08-31
JP2024028805A (ja) 2024-03-05
WO2019140150A1 (en) 2019-07-18
MX2020006171A (es) 2020-09-03
US20230279096A1 (en) 2023-09-07
JP2021510697A (ja) 2021-04-30
BR112020013144A2 (pt) 2020-12-08
KR20200108868A (ko) 2020-09-21
US20210054063A1 (en) 2021-02-25
SG11202005323SA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
US20230279096A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
KR102662228B1 (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US20180179282A1 (en) Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
JP2021521182A (ja) Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療
TW202227132A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌
EP3740506A1 (en) Methods of treating cancer with antibodies against tim3
TW202039555A (zh) ＩＬ-１β結合抗體之用途
CN113939309A (zh) 使用sEphB4-HSA融合蛋白治疗癌症
CN115443152A (zh) 使用pd-1拮抗剂、ctla4拮抗剂以及仑伐替尼或其药学上可接受的盐的组合治疗癌症的方法
CN115397861A (zh) 用于癌症的组合治疗
US20240218066A1 (en) Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer
KR20240038008A (ko) 암 치료 방법 및 조성물
TW202237081A (zh) 抗體及紫杉烷合併療法
KR20230069957A (ko) 암을 갖는 환자의 치료를 위한 pd-1 길항제 및 lag3 길항제 및 렌바티닙 또는 이의 약학적으로 허용가능한 염의 병용 요법
IL323023A (en) Combination of PD-1 and LAG-3 inhibitors for improved efficacy in melanoma treatment
EP4580756A1 (en) Methods of treating non-small cell lung cancer using mesenchymal epithelial transition factor (met)-targeted agents
CN120344265A (zh) 单独使用双特异性EGFR x CD28抗体或其与抗PD-1抗体组合使用治疗癌症的方法
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法
CN115364209A (zh) 抗pd-1抗体联合化疗治疗食管癌的用途
WO2023192478A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CN115697400A (zh) 抗cd30抗体-药物缀合物及其用于治疗非霍奇金淋巴瘤的用途
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
HK40109234A (zh) 用於治疗癌症的方法和组合物
TW202604568A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201013

WD01 Invention patent application deemed withdrawn after publication